Literature DB >> 23084518

MDM2 inhibition in liposarcoma: a step in the right direction.

Anastasia Constantinidou, Seth M Pollack, Robin L Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23084518     DOI： 10.1016/S1470-2045(12)70457-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  Senotherapeutic drugs for human intervertebral disc degeneration and low back pain.

Authors:  Hosni Cherif; Daniel G Bisson; Matthew Mannarino; Oded Rabau; Jean A Ouellet; Lisbet Haglund
Journal:  Elife       Date:  2020-08-21       Impact factor: 8.140

Review 2.  Soft Tissue Special Issue: Selected Topics in the Pathology of Adipocytic Tumors.

Authors:  Wonwoo Shon; Steven D Billings
Journal:  Head Neck Pathol       Date:  2020-01-16

3.  SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Authors:  Kate Lynn J Bill; Jeannine Garnett; Isabelle Meaux; XiaoYen Ma; Chad J Creighton; Svetlana Bolshakov; Cedric Barriere; Laurent Debussche; Alexander J Lazar; Bethany C Prudner; Lucia Casadei; Danielle Braggio; Gonzalo Lopez; Abbie Zewdu; Hemant Bid; Dina Lev; Raphael E Pollock
Journal:  Clin Cancer Res       Date:  2015-10-16       Impact factor: 12.531

Review 4.  Advances in the targeted therapy of liposarcoma.

Authors:  Zhonghai Guan; Xiongfei Yu; Haohao Wang; Haiyong Wang; Jing Zhang; Guangliang Li; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

Review 5.  Retroperitoneal liposarcoma: current insights in diagnosis and treatment.

Authors:  Lucas E Matthyssens; David Creytens; Wim P Ceelen
Journal:  Front Surg       Date:  2015-02-10

6.  Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.

Authors:  Erin K Crane; Suet-Yan Kwan; Daisy I Izaguirre; Yvonne T M Tsang; Lisa K Mullany; Zhifei Zu; JoAnne S Richards; David M Gershenson; Kwong-Kwok Wong
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 7.  Epigenetic therapy for ovarian cancer: promise and progress.

Authors:  Sara Moufarrij; Monica Dandapani; Elisa Arthofer; Stephanie Gomez; Aneil Srivastava; Micael Lopez-Acevedo; Alejandro Villagra; Katherine B Chiappinelli
Journal:  Clin Epigenetics       Date:  2019-01-15       Impact factor: 6.551
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.